PDF(Pubmed)
Abstract：
Early diagnosis is essential for the successful management of Burkholderia pseudomallei infection, but it cannot be achieved by the current gold standard culture technique. Therefore, this study aimed to develop a lateral flow immunoassay (LFIA) targeting B. pseudomallei capsular polysaccharide. The development was performed by varying nitrocellulose membrane reaction pads and chase buffers. The prototype LFIA is composed of Unisart CN95 and chase buffer containing tris-base, casein, and Surfactant 10G. The assay showed no cross-reactivity with E. coli, S. aureus, P. aeruginosa, and P. acne. The limit of detections (LODs) of the prototype LFIA was 107 and 106 CFU/mL B. pseudomallei in hemoculture medium and artificial urine, respectively. These LODs suggest that this prototype can detect melioidosis from positive hemoculture bottles but not straight from urine. Additionally, these LODs are still inferior compared to Active Melioidosis Detect (AMDTM). Overall, this prototype holds the potential to be used clinically with hemoculture bottles. However, further improvements should be considered, especially for use with urine samples.
摘要：
早期诊断对于成功治疗假性伯克霍尔德菌感染至关重要。但目前的金标准培养技术无法实现。因此,本研究旨在开发一种针对假单胞菌荚膜多糖的侧流免疫分析法（LFIA）。通过改变硝化纤维素膜反应垫和追踪缓冲液进行显影。原型LFIA由UnisartCN95和包含tris-base的追踪缓冲区组成，酪蛋白,和表面活性剂10G。该分析显示与大肠杆菌没有交叉反应，金黄色葡萄球菌，铜绿假单胞菌,还有P.痤疮.在血液培养培养基和人工尿液中，原型LFIA的检测限（LODs）为107和106CFU/mL。分别。这些LODs表明，该原型可以从阳性血液培养瓶中检测到类lioidosis，但不能直接从尿液中检测到。此外,与活跃性类鼻窦炎检测（AMDM）相比，这些LOD仍然较差。总的来说,该原型具有临床使用血液培养瓶的潜力。然而,应考虑进一步改进，特别是用于尿液样本。
